Gene therapy for familial hypercholesterolemia

Area of Science:

• Cardiovascular Medicine
• Metabolic Disorders
• Gene Therapy

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder leading to high LDL cholesterol and premature cardiovascular disease.
• LDL receptor (LDLr) deficiency is the primary cause of FH, necessitating effective treatment strategies.
• Current FH treatments include drugs, apheresis, and liver transplantation, each with limitations.

Purpose of the Study:

• To review the diagnosis, lipoprotein metabolism, and current management of familial hypercholesterolemia.
• To critically evaluate experimental LDL receptor gene transfer studies for FH treatment.
• To highlight progress in gene therapy approaches for FH from proof-of-concept to advanced regression studies.

Main Methods:

• Review of existing literature on FH, lipoprotein metabolism, and current therapies.
• Analysis of experimental studies utilizing viral vector-based LDLr gene transfer in FH animal models.
• Assessment of outcomes including hyperlipidemia correction, atherosclerosis attenuation, and lesion regression.

Main Results:

• Hepatocyte-directed LDLr gene transfer demonstrates long-term correction of hyperlipidemia in FH models.
• Viral vector-mediated LDLr gene transfer shows significant attenuation of atherosclerosis progression.
• Experimental studies indicate potential for dramatic regression of atherosclerotic lesions.

Conclusions:

• LDL receptor gene transfer is a promising therapeutic strategy for familial hypercholesterolemia.
• Gene therapy offers a potential alternative to current treatments with improved long-term outcomes.
• Further development of gene transfer technology is crucial for clinical application in FH treatment.